[{"id":"fdf62ac7-f79d-46b1-9a07-c4ce7608d067","acronym":"Ascembl","url":"https://clinicaltrials.gov/study/NCT03106779","created_at":"2021-01-17T17:34:34.885Z","updated_at":"2025-02-25T16:36:53.037Z","phase":"Phase 3","brief_title":"Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs","source_id_and_acronym":"NCT03106779 - Ascembl","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib • Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 233","initiation":"Initiation: 10/26/2017","start_date":" 10/26/2017","primary_txt":" Primary completion: 05/25/2020","primary_completion_date":" 05/25/2020","study_txt":" Completion: 12/04/2024","study_completion_date":" 12/04/2024","last_update_posted":"2025-02-06"},{"id":"cccf3900-a510-424c-9edc-f325d48c0848","acronym":"ASC2ESCALATE","url":"https://clinicaltrials.gov/study/NCT05384587","created_at":"2022-05-20T17:58:29.879Z","updated_at":"2024-07-02T16:34:37.099Z","phase":"Phase 2","brief_title":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT05384587 - ASC2ESCALATE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 02/27/2026","primary_completion_date":" 02/27/2026","study_txt":" Completion: 02/26/2027","study_completion_date":" 02/26/2027","last_update_posted":"2024-06-07"},{"id":"6d4a3258-2b1b-4296-b36c-80ae974d4943","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501614","created_at":"2021-01-18T21:33:45.485Z","updated_at":"2024-07-02T16:35:16.674Z","phase":"Phase 1/2","brief_title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04501614","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4","pipe":" | ","alterations":" BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Iclusig (ponatinib) • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 12/19/2024","primary_completion_date":" 12/19/2024","study_txt":" Completion: 01/04/2027","study_completion_date":" 01/04/2027","last_update_posted":"2024-03-04"},{"id":"ffd2ca60-82dd-404f-a539-82d708a898dd","acronym":"OPTIC","url":"https://clinicaltrials.gov/study/NCT02467270","created_at":"2021-01-18T11:52:32.635Z","updated_at":"2024-07-02T16:35:20.731Z","phase":"Phase 2","brief_title":"Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses","source_id_and_acronym":"NCT02467270 - OPTIC","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 fusion • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 283","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 04/14/2020","primary_completion_date":" 04/14/2020","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-02-06"},{"id":"af7a09a6-b7ff-45c6-968f-d00666a858dc","acronym":"AIM4CML","url":"https://clinicaltrials.gov/study/NCT04666259","created_at":"2021-01-19T20:43:43.111Z","updated_at":"2024-07-02T16:35:37.810Z","phase":"Phase 3","brief_title":"Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation","source_id_and_acronym":"NCT04666259 - AIM4CML","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 05/25/2021","start_date":" 05/25/2021","primary_txt":" Primary completion: 06/20/2023","primary_completion_date":" 06/20/2023","study_txt":" Completion: 07/05/2024","study_completion_date":" 07/05/2024","last_update_posted":"2023-09-07"},{"id":"4893e4f0-4406-4533-aee9-63908fb17f49","acronym":"FINESTdm","url":"https://clinicaltrials.gov/study/NCT04681820","created_at":"2021-01-19T20:46:48.858Z","updated_at":"2024-07-02T16:35:41.428Z","phase":"","brief_title":"Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib","source_id_and_acronym":"NCT04681820 - FINESTdm","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 V299L • BCR-ABL1 F317L • BCR-ABL1 M244V • BCR-ABL1 M351T • BCR-ABL1 H396R • BCR-ABL1 Q252H • BCR-ABL1 mutation • BCR-ABL1 E355G • BCR-ABL1 L387M • ABL1 F317L • ABL1 L387M • ABL1 M351T","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 V299L • BCR-ABL1 F317L • BCR-ABL1 M244V • BCR-ABL1 M351T • BCR-ABL1 H396R • BCR-ABL1 Q252H • BCR-ABL1 mutation • BCR-ABL1 E355G • BCR-ABL1 L387M • ABL1 F317L • ABL1 L387M • ABL1 M351T"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • Hansoh Xinfu (flumatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-08-01"},{"id":"c9859f5d-e371-4f88-a60c-1b70ab251051","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495035","created_at":"2022-08-10T12:55:24.639Z","updated_at":"2024-07-02T16:35:54.315Z","phase":"Phase 1","brief_title":"Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL","source_id_and_acronym":"NCT05495035","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • Nailike (olverembatinib) • lisaftoclax (APG-2575)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-03-02"},{"id":"3803238c-6897-4792-8192-1db65c7b3b43","acronym":"BEST","url":"https://clinicaltrials.gov/study/NCT02810990","created_at":"2021-01-18T13:47:10.028Z","updated_at":"2024-07-02T16:35:56.483Z","phase":"Phase 2","brief_title":"Bosutinib in Elderly Chronic Myeloid Leukemia","source_id_and_acronym":"NCT02810990 - BEST","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 11/17/2016","start_date":" 11/17/2016","primary_txt":" Primary completion: 04/30/2020","primary_completion_date":" 04/30/2020","study_txt":" Completion: 06/22/2022","study_completion_date":" 06/22/2022","last_update_posted":"2023-02-03"},{"id":"802b5881-b4a3-4a2c-81cc-00571e740fd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02643888","created_at":"2021-01-18T12:51:47.045Z","updated_at":"2024-07-02T16:36:01.529Z","phase":"","brief_title":"Pre-existing Kinase Domain Mutations in Ph-positive Leukemias","source_id_and_acronym":"NCT02643888","lead_sponsor":"St. Anna Kinderkrebsforschung","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2022-10-31"},{"id":"5123fd55-d0db-4a68-b1aa-6461253a8fb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02398825","created_at":"2021-01-18T11:26:40.143Z","updated_at":"2024-07-02T16:36:18.804Z","phase":"Phase 2","brief_title":"Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib","source_id_and_acronym":"NCT02398825","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 06/23/2016","start_date":" 06/23/2016","primary_txt":" Primary completion: 02/23/2021","primary_completion_date":" 02/23/2021","study_txt":" Completion: 02/01/2023","study_completion_date":" 02/01/2023","last_update_posted":"2022-01-05"}]